Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DS-6157a in Advanced GIST
NCT04276415Phase 1Terminated
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- May 2020
- Primary completion
- Mar 2022
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of DS-6157 in gastrointestinal stromal tumor (GIST) (3 arms), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoints: Dose-Limiting Toxicities and Treatment-Emergent Adverse Events. Started May 2020; status: terminated.
02
Drugs
DS-6157
03
Conditions
gastrointestinal stromal tumor (GIST)
Beyond the preview
Go deeper on NCT04276415.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04276415.